Evaxion Biotech AS (NAS:EVAX)
$ 2.42 -0.08 (-3.2%) Market Cap: 13.50 Mil Enterprise Value: 16.44 Mil PE Ratio: 0 PB Ratio: 242.00 GF Score: 19/100

Q4 2023 Evaxion Biotech A/S Earnings Call (Danish) Transcript

Apr 02, 2024 / 01:00PM GMT
Release Date Price: $3.88 (+20.12%)
Christian Kanstrup;S;CEO
Evaxion Biotech A

/-

Hello, everyone, and a very warm welcome to this Evaxion business update conference call on the back of our full year 2023 results. I'm Christine Kanstrup, I'm the CEO of Evaxion.

With me today, I have Birgitte Rønø, our Chief Scientific Officer; I have Jesper Nyegaard Nissen, our Chief Operating Officer and Chief Financial Officer. What we will be covering today is I will be giving a brief, welcome also a brief corporate update. Then we will have begin, dive into the R&D and business update, and Jesper will be covering the 2023 financial results. After a few conclusion remarks by me, we will be heading in to the Q&A session.

So looking forward to an interactive session, before getting started I just want to direct your attention to the fact that we will be talking about future today. And of course, when talking about the future that entails uncertainty. So I do direct your attention to the forward-looking statement slide, which is contained in the presentation deck for today.

With that,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot